Arbutus Biopharma Corporation
NASDAQ:ABUSBiotechnology
+$0.05 today
- Market cap
- $630.03M
- Beta
- 0.63
- P/E (TTM)
- 5.4
- EPS (TTM)
- $0.83
Volume 2.90M
Average 1.76M
ABUS Operating Cash Flow
Cash generated by the company's core business operations during the period.
Arbutus Biopharma CorporationNASDAQ: ABUS
Operating Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Operating cash flow declines year over year
Q1 FY2026 operating cash flow of $8.11M (cash outflow) fell 39.4% year over year, ahead of the -41.7% change in trailing-twelve-month operating cash flow. Sequentially, it rose 73.3% from the prior quarter. Over 3 fiscal years it compounded at +3.9% a year.
Context
- Operating cash flow amounted to 281.5% of revenue in FY2025, down 769.4 pp from a year earlier.
- Operating cash flow grew in size in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth of -39.4% holds above the trailing-twelve-month pace of -41.7%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Operating Cash Flow history
USD · from the cash flow
- Latest · FY2025
- (39.64M) USD
- Year-over-year change
- +38.9%
| Period | Period end | Operating Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (39.64M) | +38.9% |
| FY2024 | 2024-12-31 | (64.85M) | +24.5% |
| FY2023 | 2023-12-31 | (85.94M) | -143.1% |
| FY2022 | 2022-12-31 | (35.36M) | +47.6% |
| FY2021 | 2021-12-31 | (67.53M) | — |
Operating Cash Flow vs competitors
How ABUS compares with its peers on the latest reported figures
- ABUS's LTM Mar 2026 operating cash flow of $34.36M is the 7th largest of the 9 companies compared; the peer median is $52.66M.
- Its year-over-year change of -41.7% is the 6th highest of 8, against a peer median of +7.5%.
- Operating cash flow amounts to 17.9% of revenue for ABUS, versus a peer median of 58.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $634.49M | +4183.2% | — | 13.2% | |
| LTM Mar 2026 | $446.05M | +7.5% | — | 681.0% | |
| LTM Sep 2026 | $271.95M | -251.5% | +20.9% | 60.3% | |
| LTM Mar 2026 | $147.86M | +17.2% | +3.0% | — | |
| LTM Mar 2026 | $65.57M | — | +3.0% | 7115.1% | |
| LTM Mar 2026 | $39.75M | -29.3% | -21.3% | 55.9% | |
| LTM Mar 2026 | $34.36M | -41.7% | +3.9% | 17.9% | |
| LTM Mar 2026 | $20.57M | +10.2% | +14.1% | — | |
| LTM Mar 2026 | $7.84M | -85.9% | -39.0% | 11.3% | |
| Peer median (excluding ABUS) | $52.66M | +7.5% | +3.0% | 58.1% | |
Competitors are the stored peer set for ABUS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (76.25M) | (69.46M) | (72.85M) | (69.92M) | (33.5M) |
| Depreciation & Amortization | 1.75M | 1.43M | 1.4M | 1.38M | 363K |
| Deferred Income Tax | (8.18M) | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 6.42M | 7.18M | 9.3M | 8.99M | 6.95M |
| Change in Working Capital | 930K | 29.24M | (18.23M) | (2.83M) | (10.02M) |
| Accounts Receivables | 413K | (453K) | (424K) | (633K) | 1.38M |
| Inventory | (1.91M) | 0 | 0 | 0 | 0 |
| Accounts Payables | 1.91M | 5.22M | 0 | 0 | (2.11M) |
| Other Working Capital | 517K | 24.48M | (17.81M) | (2.2M) | (9.29M) |
| Other Non-Cash Items | 7.79M | (3.75M) | (5.56M) | (2.47M) | (3.43M) |
| Operating Cash Flow | (67.53M) | (35.36M) | (85.94M) | (64.85M) | (39.64M) |
| Capital Expenditures | (809K) | (512K) | (1.01M) | (182K) | 0 |
| Acquisitions (Net) | 1.81M | 0 | 0 | 0 | 0 |
| Purchases of Investments | (82.22M) | (130.43M) | (80.51M) | (141.51M) | 12.87M |
| Sales of Investments | 70.35M | 56M | 132.27M | 164.64M | 155.28M |
| Other Investing Activities | (1.81M) | 0 | 20K | 0 | (152.56M) |
| Investing Cash Flow | (12.68M) | (74.94M) | 50.77M | 22.95M | 15.58M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 134.67M | 20.32M | 29.85M | 44.12M | 5.72M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | (12.14M) | 0 | 0 | 0 | 0 |
| Other Financing Activities | 14.71M | 11.49M | 795K | 7.87M | 0 |
| Financing Cash Flow | 137.24M | 31.81M | 30.65M | 52M | 5.72M |
| Effect of Forex Changes | 5K | (22K) | 25K | (49K) | 14K |
| Net Change in Cash | 57.03M | (78.51M) | (4.49M) | 10.05M | (18.32M) |
| Free Cash Flow | (68.34M) | (35.87M) | (86.94M) | (65.03M) | (39.64M) |
Arbutus Biopharma Corporation
NASDAQ:ABUS
Intrinsic Alpha fair value
Locked
Current Price
$4.11
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.